These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 1481832)

  • 1. Double-blind, placebo-controlled crossover study of folinic acid (Leucovorin for the treatment of fragile X syndrome.
    Strom CM; Brusca RM; Pizzi WJ
    Am J Med Genet; 1992 Nov; 44(5):676-82. PubMed ID: 1481832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome.
    Berry-Kravis E; Sumis A; Hervey C; Nelson M; Porges SW; Weng N; Weiler IJ; Greenough WT
    J Dev Behav Pediatr; 2008 Aug; 29(4):293-302. PubMed ID: 18698192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis.
    Buckley LM; Vacek PM; Cooper SM
    J Rheumatol; 1990 Sep; 17(9):1158-61. PubMed ID: 2132565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and electroencephalographic effects of folinic acid treatment in Rett syndrome patients.
    Hagebeuk EE; Koelman JH; Duran M; Abeling NG; Vyth A; Poll-The BT
    J Child Neurol; 2011 Jun; 26(6):718-23. PubMed ID: 21427443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent use of folinic acid and methotrexate in rheumatoid arthritis.
    Hanrahan PS; Russell AS
    J Rheumatol; 1988 Jul; 15(7):1078-80. PubMed ID: 3050087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the effect of docosahexaenoic acid on cognitive functions in healthy, preschool children: a randomized, placebo-controlled, double-blind study.
    Ryan AS; Nelson EB
    Clin Pediatr (Phila); 2008 May; 47(4):355-62. PubMed ID: 18180340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid therapy in the fragile X syndrome.
    Brown WT; Jenkins EC; Friedman E; Brooks J; Cohen IL; Duncan C; Hill AL; Malik MN; Morris V; Wolf E
    Am J Med Genet; 1984 Jan; 17(1):289-97. PubMed ID: 6711601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial.
    Berry-Kravis EM; Hessl D; Rathmell B; Zarevics P; Cherubini M; Walton-Bowen K; Mu Y; Nguyen DV; Gonzalez-Heydrich J; Wang PP; Carpenter RL; Bear MF; Hagerman RJ
    Sci Transl Med; 2012 Sep; 4(152):152ra127. PubMed ID: 22993294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension.
    Singh TP; Rohit M; Grover A; Malhotra S; Vijayvergiya R
    Am Heart J; 2006 Apr; 151(4):851.e1-5. PubMed ID: 16569546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
    Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
    Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
    Spencer TJ; Abikoff HB; Connor DF; Biederman J; Pliszka SR; Boellner S; Read SC; Pratt R
    Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial.
    Frye RE; Slattery J; Delhey L; Furgerson B; Strickland T; Tippett M; Sailey A; Wynne R; Rose S; Melnyk S; Jill James S; Sequeira JM; Quadros EV
    Mol Psychiatry; 2018 Feb; 23(2):247-256. PubMed ID: 27752075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open-label use of placebos in the treatment of ADHD: a pilot study.
    Sandler AD; Bodfish JW
    Child Care Health Dev; 2008 Jan; 34(1):104-10. PubMed ID: 18171451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
    Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
    J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
    Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder.
    Voigt RG; Llorente AM; Jensen CL; Fraley JK; Berretta MC; Heird WC
    J Pediatr; 2001 Aug; 139(2):189-96. PubMed ID: 11487742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.